

IS ICER INCREASING INFLUENCE IN THE USA OVER TIME?

Authors: Magdi Stino¹, Anita Burrell²
Affiliations: 1. EVERSANA and 2. Anita Burrell Consulting



OBJECTIVES

- Recent high-profile product launches, notably onasemnogene abeparvovec (Zolgensma), have reignited the debate on healthcare costs in the US.
- The Institute for Clinical and Economic Review (ICER) is an independent research organization that determines value-based price benchmarks in the American pharmaceutical market.
- This study examines recent high-profile launches to understand the interaction between ICER value-based price benchmarks and intended vs. actual launch prices.

METHODS

- Four recent, high-profile launches were identified:
 - pembrolizumab (Keytruda, 2015);
 - axicabtagene ciloleucel (Yescarta, 2017);
 - voretigene neparvovec (Luxturna, 2018);
 - onasemnogene abeparvovec (Zolgensma, 2019).
- Prices associated with cost per quality-adjusted life-year (QALY) and/or life-year gained (LYG) benchmarks were identified from their respective ICER assessments along with the price intended for launch by the manufacturer.
- Actual launch prices, identified Pricentric One[®] by EVERSANA database, were compared to ICER benchmarks.

RESULTS



- The intended launch price for pembrolizumab (Keytruda) of \$4,381/vial was almost identical with the actual launch price (\$4,316/vial), which was above the ICER-determined price of \$1,719 at a \$100K/QALY threshold and \$2,694 at \$150K/QALY.
- The intended launch price for axicabtagene ciloleucel (Yescarta) was \$373,000, equal to the actual launch price and falling between \$100K/QALY and \$150K/QALY (\$340,797 and \$524,015).
- The price for voretigene neparvovec (Luxturna) was initially noted as \$850K and the actual launch price was \$425K.
- For age 15, this fell between \$250K and \$500K/QALY (US healthcare perspective) and \$100K to \$150K/QALY (US Modified Societal perspective).
- For age 3, this fell between \$100K to \$150K/QALY (US Healthcare perspective) and was cost-effective at \$50K/QALY (US Modified Societal perspective).
- Onasemnogene abeparvovec (Zolgensma) launched at \$2,125,000 and was cost-effective at an updated benchmark of \$150,000/LYG.

CONCLUSIONS

- These results indicate that ICER is becoming increasingly important as a price benchmark.
- While the prices for intended and actual launch were above the ICER benchmarks for the earliest high profile product, more recent products have launched at reduced prices in line with ICER benchmarks.
- The most recent launch was outside the original cost effective range but was endorsed by ICER after additional information was submitted.

REFERENCES

- 1) [Keytruda] - Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value Based Price Benchmarks. Available from: https://icer-review.org/wp-content/uploads/2016/10/MWCEPAC_NSCLC_Final_Evidence_Report_Meeting_Summary_110116.pdf. [Accessed June 10, 2019].
- 2)[Luxturna] - Voretigene Neparvovec for Biallelic RPE65-Mediated Retinal Disease: Effectiveness and Value. Available from: https://icer-review.org/wp-content/uploads/2017/06/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf. [Accessed June 10, 2019].
- 3)Yescarta] - Chimeric Antigen Receptor T-Cell Therapy for BCell Cancers: Effectiveness and Value. Available from: https://icer-review.org/wp-content/uploads/2017/07/ICER_CAR_T_Final_Evidence_Report_032318.pdf. [Accessed June 10, 2019].
- 4)[Zolgensma] - Spinraza[®] and Zolgensma[®] for Spinal Muscular Atrophy: Effectiveness and Value. Available from: https://icer-review.org/wp-content/uploads/2018/07/ICER_SMA_Final_Evidence_Report_052419.pdf. [Accessed June 10, 2019].
- 5)Pricentric One[®] (EVERSANA, <https://pricentric.alscg.com>)



EVERSANA[™]



PRICENTRIC ONE[™]
BY EVERSANA[™]